Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1998-04-23
2000-06-27
Johnson, Nancy A.
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
424 9371, 4241841, 4241851, 4242041, 4242771, 4242651, 424 937, 514 2, 530351, 530300, A61K 3820, A61K 4505, A61K 3912, A61K 39002, C07K 1454
Patent
active
060803991
ABSTRACT:
The invention provides methods of inducing the production of cytolytic T lymphocytes directed against malignancy or infectious agent by a mammal and treating such disease such that deleterious side effects are minimized and treatment of metastatic melanomas are surprisingly and dramatically improved.
REFERENCES:
patent: 5571515 (1996-11-01), Scott et al.
patent: 5591430 (1997-01-01), Townsend et al.
patent: 5662907 (1997-09-01), Kubo et al.
patent: 5665347 (1997-09-01), Metzger et al.
patent: 5674749 (1997-10-01), Chen et al.
patent: 5723127 (1998-03-01), Scott et al.
patent: 5744132 (1998-04-01), Warne et al.
patent: 5756085 (1998-05-01), Sykes et al.
patent: 5891432 (1999-04-01), Hoo
Mukherji, B. et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA, 92:8078-8082, Sep. 1995.
Shurin, M.R. et al. Antitumor activities of IL-12 and mechanisms of action. In: IL-12. Chemical Immunology, Adorini L. (ed): Basel, Karger, 68: 153-174, 1997.
Uyttenhove, C. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against of P1A-encoded tumor antigen. Int. J. Cancer, 70:349-356.
Bianchi et al., "IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells," J. Immunology, 157:1589-1597, 1996.
Castelli et al, "Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes," J. Exp. Med., 181:363-368, 1995.
Chen et al., "Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients," Chest, 112:960-966, 1997.
Fallarino, Ashikari, Boon, Gajewski, "Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12-but not B7-1-transfected tumor cells," Inter. Immunol., 9(9):1259-1269, 1997.
Fallarino et al., "Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo," J. Immunology, 156:1095-1100, 1996.
Fleischhauer et al., Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene Mage-3, Int. J. Cancer, 68:622-628, 1996.
Gajewski, Renauld, Van Pel, Boon, "Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine anti-tumor cytolytic T lymphocytes in vitro," J. Immunol., 154:5637-5648, 1995.
Gajewski, "B7-1 but not B7-2 efficiently costimulates CD8.sup.+ T lymphocytes in the P815 tumor system in vitro," J. Immunol., 156:465-472, 1996.
Gajewski, Uyttenhove, Fallarino, Boon. "Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: Superiority of B7-1 over B7-2 for active tumor immunization," J. Immunol. 156:2909-2917, 1996.
Grohmann et al., "Dendritic cells and interleukin 12 as adjuvants for tumor-specific vaccines," IN: Dendritic cells in fundamental and clinical immunology, Ricciardi-Castagnoli (ed.), Advances in Experimental Medicine and Biology, 417:579-582, 1997.
Irvine et al., "Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases," J. Immunology, 156:238-245, 1996.
Jaeger et al., "Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens," Int. J. Cancer, 66:162-169, 1996.
Jaeger et al., "Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo," Int. J. Cancer, 67:54-62, 1996.
Kang et al., "Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins," Cancer Res., 57:202-205, 1997.
Katayose et al., "MUCI-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth," Cancer Res., 56:4205-4212, 1996.
Leonard et al., Effects of single-dose interleukin-12 exposure on interleukin-12 associated toxicity and interferon-.gamma. production, Blood, 90(7):2541-2548, 1997.
Marchand et al., "Tumor regression responses in melanoma patients treated with a peptide encoded by gene Mage-3," Int. J. Cancer, 63:883-885, 1995.
Reynolds et al., "A polyvalent melanoma vaccine induces a CD8 T cell response to Mart-1 and Mage-3 peptides," 87th Annual Meeting, Proceedings of the American Association for Cancer Research, Washington, D.C., 37:3350, Abstract #3350, 1996.
Reynolds et al., "Stimulation of CD8+ T cell responses to Mage-3 and Melan-A/Mart-1 by immunization to a polyvalent melanoma vaccine," Int. J. Cancer, 72:972-976, 1997.
Ribas et al., "Genetic immunization for the melanoma antigen Mart-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells," Cancer Res., 57:2865-2869, 1997.
Romero et al., "Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/Mart-1 antigenic peptide in melanoma," J. Immunology, 159:2366-2374, 1997.
Tahara et al., "Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo," Cancer Res., 54:182-189, 1994.
Tanaka et al., "Induction of antitumor cytotoxic T lymphocytes with a Mage-3 encoded synthetic peptide presented by human leukocytes antigen-A24," Cancer Res., 57:4465-4468, 1997.
Valmori et al., "Analysis of Mage-3 specific cytolytic T lumphocytes in human leukocyte antigen-A2 melanoma patients," Cancer Res., 57:735-741, 1997.
van der Bruggen et al., "A peptide encoded by human gene Mage-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing Mage-3," Eur. J. Immunol., 24:3038-3043, 1994.
Zajac et al., "Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccina virus encoding Mart-1/Melan-A 27-35 epitope," Int. J. Cancer, 71:491-496, 1997.
Zitvogel et al., "IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo," In: Interleukin 12: Cellular and MolecularImmunology of an Important Regulatory Cytokine, Lotze et al. eds., Annals of the New York Academy of Sciences, 793:284-293, 1996.
Fallarino Francesca
Gajewski Thomas F.
ARCH Development Corporation
Holleran Anne L.
Johnson Nancy A.
LandOfFree
Vaccine adjuvants for immunotherapy of melanoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine adjuvants for immunotherapy of melanoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine adjuvants for immunotherapy of melanoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1781940